Professor Colin Baigent
- 3C: A CAMPATH, Calcineurin inhibitor reduction and Chronic allograft nephropathy trial
- ATT: Antithrombotic Trialists' Collaboration
- Coxib and traditional NSAID (CNT) Collaboration
- CTT: Cholesterol Treatment Trialists' Collaboration
- EMPA-KIDNEY: the study of heart and kidney protection with empagliflozin
- Gastroprotectant Trialists' (GPT) Collaboration
- Mexico City Prospective Study
- MTT: Marfan Treatment Trialists' Collaboration
- Research Regulation
- SHARP: Study of Heart and Renal Protection
- STT: Stroke Thrombolysis Trialists' Collaboration
- Trials Methodology
- UK HARP III
Professor of Epidemiology and Director, MRC PHRU
- Deputy Director, CTSU
Colin Baigent studied Medicine at Bristol and Oxford University (1983-89), having originally studied Mathematics at Oxford (1980-83).
He became an MRC career scientist in 2002, and in 2006 was appointed Professor of Epidemiology at Oxford. From July 2013, he became Deputy Director of CTSU.
His main interest is in cardiovascular epidemiology, and most particularly the design, conduct and application of large-scale randomised trials in cardiovascular disease. His research includes the coordination of meta-analyses of randomised trials, typically with individual participant data, resulting in landmark papers that have helped determine the effects of aspirin (and other antiplatelet drugs), non-steroidal anti-inflammatory drugs, fibrinolytic therapy, and statins in different types of patients. His group has also contributed to a better understanding of cardiovascular disease in patients with renal impairment through the Study of Heart and Renal Protection (SHARP), the largest ever in patients with moderate-to-severe chronic kidney disease (CKD), recruiting 9438 patients in nearly 400 hospitals in 18 countries.
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials.
Cholesterol Treatment Trialists' Collaboration None., (2019), Lancet, 393, 407 - 415
Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.
ASCEND Study Collaborative Group None. et al, (2018), N Engl J Med, 379, 1540 - 1550
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
ASCEND Study Collaborative Group None. et al, (2018), N Engl J Med, 379, 1529 - 1539
Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease.
Haynes R. et al, (2018), Circulation, 138, 1505 - 1514
Effects of Sacubitril/Valsartan Versus Irbesartan in Patients with Chronic Kidney Disease: A Randomised Double-Blind Trial.
Haynes R. et al, (2018), Circulation